Management of Insomnia in Elderly Patients

First-Line Approach: Non-Pharmacologic Treatment

The American Geriatrics Society recommends cognitive behavioral therapy for insomnia (CBT-I) as the first-line treatment for elderly patients with chronic insomnia, which provides sustained long-term benefits without the risks associated with hypnotic medications 1, 2
Behavioral interventions, such as stimulus control and sleep hygiene, must be attempted before or alongside any pharmacologic therapy to provide sustained long-term benefits without the risks associated with hypnotic medications 1, 2
CBT-I combines stimulus control, sleep restriction, relaxation therapy, and cognitive restructuring, and multiple studies demonstrate its efficacy in older adults, with benefits better sustained over time compared to pharmacotherapy alone 1, 2

The American Geriatrics Society recommends low-dose nonbenzodiazepine receptor agonists (Z-drugs) such as eszopiclone 1-2 mg or zolpidem 5 mg as preferred agents for elderly patients with insomnia, due to their lower frequency and severity of adverse effects compared to older benzodiazepines 1, 2
The NIH State-of-Science Conference concluded that benzodiazepine receptor agonists (Z-drugs) are efficacious for short-term insomnia management with lower frequency and severity of adverse effects compared to older benzodiazepines 1, 2
Benzodiazepines increase the risk of falls, cognitive impairment, dependence, and should be avoided in elderly patients, especially those with dementia or irregular sleep-wake rhythm disorder 2, 3

The American Academy of Sleep Medicine suggests light therapy (2500-5000 lux for 1-2 hours between 09:00-11:00) over pharmacotherapy for irregular sleep-wake rhythm disorder in elderly patients with dementia 3
Hypnotic medications should be avoided in demented elderly patients with irregular sleep-wake rhythm disorder (ISWRD) due to increased risk of falls and adverse events outweighing potential benefits 3

The American Geriatrics Society recommends monitoring for respiratory depression, confusion, delirium, and fall risk, especially in patients with respiratory compromise or cognitive impairment, when using sleep medications 3
Pharmacotherapy should be used for the shortest duration possible, with behavioral interventions providing the foundation for long-term management, to minimize the risk of adverse effects and dependence 1, 2

The American Academy of Sleep Medicine recommends eszopiclone (1-2 mg) as a first-line treatment for elderly patients with insomnia, due to its efficacy in improving sleep onset and maintenance with minimal impact on sleep architecture 4
The American Academy of Sleep Medicine suggests that eszopiclone is particularly effective for elderly patients with both sleep onset and maintenance insomnia, with a starting dose of 1 mg at bedtime 5
Zolpidem (5 mg) and zolpidem controlled-release (6.25 mg) are alternative Z-drugs for specific insomnia presentations, primarily for sleep-onset insomnia and both sleep onset and maintenance, respectively 5
Ramelteon (8 mg) may be considered for patients with primarily sleep onset difficulties, and can be used alongside existing melatonin supplementation 5

Elderly patients have reduced clearance of sedative-hypnotics and increased sensitivity to peak drug effects, requiring lower starting doses and cautious titration 4, 6
The American Geriatrics Society recommends starting with the lowest available dose and titrating cautiously to minimize the risk of adverse effects 4, 5

The American Academy of Sleep Medicine recommends avoiding benzodiazepines in elderly patients due to increased risk of falls, cognitive impairment, and dependence 7, 5

The American Academy of Sleep Medicine suggests administering sleep medications on an empty stomach to maximize effectiveness, and allowing for appropriate sleep time (7-8 hours) before morning activities 5

The American Geriatrics Society recommends combining pharmacologic treatment with cognitive behavioral therapy for insomnia (CBT-I) when possible, and reinforcing sleep hygiene measures to improve sleep outcomes 4, 6

The American College of Physicians recommends considering alternative sleep medications due to the increased risk of falls and fractures associated with zolpidem, with an adjusted odds ratio of 1.72, and a 4.28-fold increased risk of falls in hospitalized patients 8
Zolpidem is associated with cognitive impairment, including memory impairment, confusion, and psychiatric adverse events, with low to moderate strength evidence 8
The use of zolpidem is linked to an increased mortality risk, with inconsistent but concerning mortality signals, according to the American Geriatrics Society 8

The American Academy of Sleep Medicine recommends low-dose doxepin (3-6 mg) as a first-line option for sleep maintenance insomnia in elderly patients, which improves total sleep time and wake after sleep onset with low to moderate strength evidence 9
Low-dose doxepin has a superior safety profile, with adverse effects and study withdrawals not significantly differing from placebo in elderly patients, as stated by the National Institute on Aging 9
The American College of Physicians suggests ramelteon (8 mg) as a second-line option for sleep onset insomnia, with no abuse potential or significant cognitive/motor impairment, and suitable for elderly patients with comorbid depression 9
Benzodiazepines should be avoided due to increased risk of falls, cognitive impairment, dependence, and dementia, especially higher-dose and long-acting agents, according to the Centers for Disease Control and Prevention 9